Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 116

    Alembic Pharma gets USFDA nod for generic version of Tamiflu capsules

    Alembic Pharma gets USFDA nod for generic version of Tamiflu capsules

    Farhat Nasim25 Jun 2019 11:54 AM IST
    The approved product, Oseltamivir Phosphate capsule is therapeutically equivalent to the reference listed drug (RLD), Tamiflu Capsules of Hoffman-La...
    Indian Immunologicals invests Rs 75 crore to set up new Sterile Filling Facility in Telangana

    Indian Immunologicals invests Rs 75 crore to set up new Sterile Filling Facility in Telangana

    Farhat Nasim25 Jun 2019 11:36 AM IST
    With this investment of Rs 75 crores in the upcoming filling facility, Indian Immunologicals Limited expects to increase its capacity to supply...
    Dr Reddys unveils generic version of Vitamin K1 injection in US

    Dr Reddys unveils generic version of Vitamin K1 injection in US

    Medical Dialogues Bureau25 Jun 2019 10:52 AM IST
    The Vitamin K1 (Phytonadione) for Injectable Emulsion USP, 10 mg/ml brand and generic, had combined US sales of approximately USD 46.6 million MAT for...
    Lawsuit: Generic drug makers used code to fix price increases

    Lawsuit: Generic drug makers used code to fix price increases

    Medical Dialogues Bureau25 Jun 2019 9:15 AM IST
    The alleged conspiracy targeted more than 100 different generic drug(s), including treatments for diabetes, cancer, arthritis and other medical...
    Oklahoma judge approves Teva Pharma USD 85 million opioid settlement

    Oklahoma judge approves Teva Pharma USD 85 million opioid settlement

    Medical Dialogues Bureau25 Jun 2019 9:00 AM IST
    U.S: An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd (Teva Pharma) resolving claims by...
    Novartis, Glenmark enter partnership to commercialize, distribute respiratory drugs Seebri, Onbrize, Ultibro

    Novartis, Glenmark enter partnership to commercialize, distribute respiratory drugs Seebri, Onbrize, Ultibro

    Medical Dialogues Bureau24 Jun 2019 3:02 PM IST
    Under the terms of the agreement, Novartis will remain the holder of the registration of the drugs Seebri, Onbrize and Ultibro and will be responsible...
    Alembic Pharma gets USFDA nod for Bromfenac Ophthalmic Solution

    Alembic Pharma gets USFDA nod for Bromfenac Ophthalmic Solution

    Farhat Nasim24 Jun 2019 12:25 PM IST
    The approved product, Bromfenac Ophthalmic Solution is therapeutically equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution,...
    Dr Reddys gets two USFDA observations for Vizag plants

    Dr Reddys gets two USFDA observations for Vizag plants

    Farhat Nasim24 Jun 2019 11:09 AM IST
    Hyderabad: City-based Dr Reddy's Laboratories (Dr Reddys/ DRL) has reportedly fallen under the US health regulator's scanner. The company has been...
    Glenmark Pharma Ryaltris gets Complete Response Letter from USFDA

    Glenmark Pharma Ryaltris gets Complete Response Letter from USFDA

    Medical Dialogues Bureau24 Jun 2019 9:30 AM IST
    The CRL cites deficiencies in the Drug Master File pertaining to one of the active pharmaceutical ingredients and in manufacturing facilities,...
    GSK Pharma to optimise product portfolio to drive growth in India

    GSK Pharma to optimise product portfolio to drive growth in India

    Medical Dialogues Bureau24 Jun 2019 9:19 AM IST
    GSK is also looking to launch some new products in the country over the next 15 months as it adopts a more structured approach to engage trade channel...
    No formal warning issued from AIIMS regarding adverse effects of e-cigarettes: Minister informs Parliament

    No formal warning issued from AIIMS regarding adverse effects of e-cigarettes: Minister informs Parliament

    Medical Dialogues Bureau23 Jun 2019 10:15 AM IST
    In response to a question on whether AIIMS has issued any warning regarding harmful effects of e-cigarettes, he said the premier medical institute has...
    USFDA declines to approve Daiichi Sankyo blood cancer treatment Quizartinib

    USFDA declines to approve Daiichi Sankyo blood cancer treatment Quizartinib

    Farhat Nasim23 Jun 2019 10:00 AM IST
    The decision follows an advisory committee meeting, held in May, where independent advisers to the U.S. regulator voted 8-3 against the drug's...
    PrevNext

    Popular Stories

    OncoStem Diagnostics named

    OncoStem Diagnostics named 'Best Innovation- Cancer Risk Assessment' by NASSCOM Life sciences and...

    Supreme Court to hear PIL seeking direction to govt for banning unregulated medical devices

    Supreme Court to hear PIL seeking direction to govt for banning unregulated medical devices

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Strides Pharma appoints former Cipla Chief Operating Officer Dr R Ananthanarayanan as new CEO, MD

    Strides Pharma appoints former Cipla Chief Operating Officer Dr R Ananthanarayanan as new CEO, MD

    Top Pharmacy Courses That Rule the Industry

    Top Pharmacy Courses That Rule the Industry

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok